

Published in final edited form as:

Respir Med. 2013 November ; 107(11): . doi:10.1016/j.rmed.2013.08.018.

Driver mutations among never smoking female lung cancer tissues in China identify unique *EGFR* and *KRAS* mutation pattern associated with household coal burning

H. Dean Hosgood III^{1,2,*}, William Pao³, Nathaniel Rothman¹, Wei Hu¹, Yumei Helen Pan³, Kyle Kuchinsky⁴, Kirk D. Jones⁴, Jun Xu⁵, Roel Vermeulen⁶, Jeff Simko⁴, and Qing Lan¹

¹Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, NCI, NIH, DHHS, Bethesda, MD ²Division of Epidemiology, Albert Einstein College of Medicine, Bronx, NY ³Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, TN ⁴Department of Anatomic Pathology, University of California, San Francisco, San Francisco, CA ⁵Department of Community Medicine, The University of Hong Kong School of Public Health, Hong Kong ⁶Utrecht University, Utrecht, Netherlands

Abstract

Lung cancer in never smokers, which has been partially attributed to household solid fuel use (i.e. coal), is etiologically and clinically different from lung cancer attributed to tobacco smoking. To explore the spectrum of driver mutations among lung cancer tissues from never smokers, specifically in a population where high lung cancer rates have been attributed to indoor air pollution from domestic coal use, multiplexed assays were used to detect >40 point mutations, insertions, and deletions (*EGFR*, *KRAS*, *BRAF*, *HER2*, *NRAS*, *PIK3CA*, *MEK1*, *AKT1*, and *PTEN*) among the lung tumors of confirmed never smoking females from Xuanwei, China [32 adenocarcinomas (ADCs), 7 squamous cell carcinomas (SCCs), 1 adenosquamous carcinoma (ADSC)]. *EGFR* mutations were detected in 35% of tumors. 46% of these involved *EGFR* exon 18 G719X, while 14% were exon 21 L858R mutations. *KRAS* mutations, all of which were G12C_34G>T, were observed in 15% of tumors. *EGFR* and *KRAS* mutations were mutually exclusive, and no mutations were observed in the other tested genes. Most point mutations were transversions and were also found in tumors from patients who used coal in their homes. Our high mutation frequencies in *EGFR* exon 18 and *KRAS* and low mutation frequency in *EGFR* exon 21 are strikingly divergent from those in other smoking and never smoking populations from Asia. Given that our subjects live in a region where coal is typically burned indoors, our findings provide new insights into the pathogenesis of lung cancer among never smoking females exposed to indoor air pollution from coal.

© 2013 Elsevier Ltd. All rights reserved.

*To whom proofs and correspondence should be addressed: H. Dean Hosgood, (dean.hosgood@einstein.yu.edu), phone (718-430-2138), fax (718-430-8780), Albert Einstein College of Medicine, Department of Epidemiology and Population Health, Division of Epidemiology, 1300 Morris Park Ave., Belfer 1309, Bronx, New York 10461.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflicts of interest: None to declare.

Keywords

EGFR; KRAS; lung cancer; never smoking; China; driver mutations; tumor tissue

Introduction

Lung cancer has been the most common cancer in the world for over two decades [1]. Globally, about 53% of lung cancer cases in women and 15% of lung cancer cases in men are not attributable to tobacco use [2]. Evidence suggest that lung cancer in never smokers has unique risk factors, clinical features, and histological distributions when compared to lung cancer cases attributed to smoking tobacco, with lung cancer in never smokers presenting predominately as adenocarcinoma and in females [3, 4].

Given that most women throughout Asia historically do not smoke, they constitute an ideal study population which can enable the elucidation of risk factors for developing never smoking lung cancer. Interestingly, never smoking women in certain regions of Asia experience some of the highest lung cancer rates in the world [5, 6]. These rates have been partially attributed to known environmental risk factors such as fuel combustion byproducts from indoor heating and cooking and environmental tobacco smoke [5, 7]. Xuanwei, China is a unique region in which to study these environmental exposures as it has the highest female prevalence of lung cancer in China and a majority of women are never smokers [6, 8, 9]. Nearly all Xuanwei women have substantial exposure to indoor air pollution from domestic fuel combustion for heating and cooking [10, 11], an established risk factor for lung cancer [12].

Driver mutations occur in genes that encode signaling proteins that play key roles in the regulation of cell death and proliferation [13]. Many driver mutations have been found in lung cancer and are now used to classify tumors at the molecular level. Given the dramatic and prolonged benefit in patients with *EGFR* mutant tumors treated with *EGFR* tyrosine kinase inhibitors [14], most reports have focused on *EGFR* mutations; however, few studies have characterized tumors specifically from never smokers [15, 16], and even fewer studies have evaluated the impact of environmental exposures on these mutation patterns. To date, most reports have evaluated mutations in relation to environmental tobacco smoke and radon exposures [17–19]. For this reason, this study sought to evaluate *EGFR*, *KRAS*, *BRAF*, *HER2*, *NRAS*, *PIK3CA*, *MEK1*, *AKT1*, and *PTEN* driver mutations present in tumor samples collected in Xuanwei to produce new insights into the pathogenesis of lung cancer among never smoking females exposed to indoor air pollution from coal.

Methods

Lung cancer patients presenting to hospitals in Xuanwei, China were eligible for participation in our ongoing study. During surgery, a piece of tumor from the lung was extracted, formalin-fixed, and paraffin embedded. This study was reviewed and approved by the National Institutes of Health's Office of Human Subjects Research.

In total, 40 formalin-fixed paraffin embedded (FFPE) tissues were collected from never smoking female lung cancer cases in Xuanwei. Expert consensus review (by KDJ and JS) of the FFPE tissue samples from this series of 40 never smoking female lung cancer cases was conducted to determine histology and to identify viable tumor areas for dissection and subsequent nucleic acid isolation. The selected tumor areas for use in DNA isolation were required to contain at least 50% viable tumor cells. Of the 40 cases, 32 (80.0%) of these

never smoking female cases were adenocarcinomas, seven (17.5%) were squamous cell carcinomas, and one (2.5%) was an adenosquamous carcinoma.

Two multiplexed assays were used to evaluate the FFPE tissue DNA for more than 40 recurrent mutations in 9 genes relevant to existing and emerging targeted lung cancer therapies. First, the amplification of DNA through Applied Biosystem's SNaPshot was used to detect 38 different recurrent point mutations in 8 driver genes (*EGFR*, *KRAS*, *BRAF*, *NRAS*, *PIK3CA*, *MEK1*, *AKT1*, and *PTEN*). This platform involved multiplexed amplification of DNA targets by the polymerase chain reaction (PCR) with unlabeled oligonucleotide primers, multiplexed single-base primer extension with fluorescently-labeled dideoxynucleotides, and analysis of labeled primer-extension products by capillary electrophoresis. The second assay was a separate PCR-based sizing technique that simultaneously assesses tumors for recurrent insertions in *EGFR* and *HER2* and deletions in *EGFR* that would not be comprehensively detected by the SNaPshot technique. This assay was used for *EGFR* exon 19 deletions, *EGFR* exon 20 insertions, and *HER2* exon 20 insertions. Compared to direct sequencing, these assays offer higher analytical sensitivity and reduced complexity. They also provide a robust and accessible approach for the rapid identification of important mutations in lung cancer [20].

Chi-squared and Fischer's exact tests were used to compare the number of specific mutations between subgroups. Two-sided p-values are reported.

Results

The 40 FFPE tissues collected among female never smoking lung cancer cases in Xuanwei were predominantly adenocarcinomas (80.0%) and to a lesser extent squamous cell carcinomas (17.5%). The mean (\pm standard deviation) age of these cases was 46.5 years old (\pm 10.0 years) (Table 1).

Mutations in tumor tissues were observed only in *EGFR* and *KRAS*. No mutations were detected for *BRAF*, *NRAS*, *PIK3CA*, *MEK1*, *HER2*, *AKT1*, or *PTEN*. *KRAS* mutations were found in 15% of all tissues, and *EGFR* mutations were found in 35% of all tissues (Figure 1). When stratifying the *EGFR* mutations by type, point mutations were found in 22% of all tissues, deletions in 10%, and insertions in 3% (Figure 1). All *EGFR* and *KRAS* mutations were mutually exclusive. While the distribution of *EGFR* mutations suggests the potential for variability by age, the distributions were fairly similar by histology and differentiation (Table 2).

Among the 15 *EGFR* mutations, nine were point mutations, four were exon 19 deletions, and one was an exon 20 insertion (Table 3). Eight point mutations were in adenocarcinomas, with one tissue having two different *EGFR* point mutations, and one mutation was in a squamous cell carcinoma. *EGFR* point mutations were predominately G719 mutations ($n = 7$, or 46% of all *EGFR* mutations) on exon 18 (Figure 2). *EGFR* point mutations were also observed on exon 21 (L858R, $n = 2$, or 13% of all *EGFR* mutations). Three adenocarcinomas and one squamous cell carcinoma harbored exon 19 deletions, and one adenocarcinoma contained an exon 20 insertion. Among the six *KRAS* mutations, all were *KRAS* G12C_34G>T point mutations (Table 3). Five of these mutations were found in adenocarcinomas and 1 was in a squamous cell carcinoma.

EGFR and *KRAS* mutations were observed in both adenocarcinomas and squamous cell carcinomas and for a range of differentiations and ages (Table 3). One consistency observed for all point mutations was the use of only coal for the case's household cooking and heating needs, which may not be surprising given that most patients were coal-only users. This

consistency was not observed for *EGFR* deletions. No significant differences were observed when comparing mutation distributions by coal type: bituminous coal (n = 21) versus anthracite coal (n = 12) (p >0.05).

Discussion

We have conducted, to the best of our knowledge, the first analysis of point mutations, insertions, and deletions in a spectra of known lung cancer driver genes that includes genes beyond *EGFR* and *KRAS*, in tumor tissues from a population of never smokers who used solid fuel in their home for heating and cooking. When compared to previously studied populations, our results suggest a unique distribution of *EGFR* and *KRAS* mutations. Specifically, our observed point mutation frequencies of *EGFR* exons 18 and 21, suggest a unique mutational pattern in lung cancer tumors for subjects with substantial indoor air pollution exposure from coal burning.

Our assay evaluated the following *EGFR* point mutations: G719: p.G719C c.2155G_T, p.G719S c.2155G_A, p.G719A c.2156G_C; T790M: p.T790M c.2369C_T; L858: p.L858R c.2573T_G; L861: p.L861Q c.2582T_A. Similar to other studies in never smokers [18, 19, 21], we found a lack of association between clinicopathological characteristics and *EGFR* mutations. In terms of overall *EGFR* mutation frequencies, our results are also consistent with previous reports that about 30% of lung cancer tumors from Eastern Asia harbor *EGFR* mutations, and about 40% of lung cancer tumors from females harbor *EGFR* mutations [22]. When summarizing all lung cancer histologies, across multiple ethnicities including both those that do and do not smoke tobacco, *EGFR* mutations are mostly exon 19 deletions (44%) and exon 21 L858R point mutations (41%), with only limited exon 20 insertions (5%) and exon 18 G719 point mutations (4%) [22]. Our observations are fairly consistent with the findings from characterizations of tissues from never smoking females both in East Asia and in North America, with respect to the percentage of *EGFR* mutations that are exon 19 deletions [15, 18, 19, 21, 23] and exon 20 insertions [21].

In contrast, a striking difference exists between our findings and those typically found for the incidence of G719 mutations in exon 18 (50% versus 4%) and L858 mutations in exon 21 (14% versus 41%). Interestingly, a recent characterization of lung adenocarcinomas from never smoking females in Shanghai [15] found virtually identical mutation rates for exon 18 (3%) and exon 21 mutations (42%) as those typically found across ethnicities when including both those that do and do not smoke tobacco [22]. When taken together, these results suggest that not only is our high incidence of G719 mutations in exon 18 and unusually low incidence of L858 mutations in exon 21 different from the general population of all lung cancer tumors, it is also divergent from tumors collected from other never smoking female populations in China. Indeed, the distribution of mutations we observed among all lung cancers was significantly different than those previously observed in the general population [22] (p < 0.0001) and in a series of never smoking females from Asia [21] (p < 0.0001) (Figure 2). There was no statistical difference between the mutation distributions of these two comparative, previously reported populations (p > 0.05). Of note, PCR carryover of the *EGFR* exon 18 mutation is unlikely to explain our results, as no template controls are used throughout our assay [20]. Recently, the TCGA study of 178 squamous cell lung cancer samples found no *EGFR* L858R or exon 19 deletions [24], further highlighting the uniqueness of our study population and findings.

The high percentage of samples with *KRAS* mutations (15%) in our series is also of interest primarily because *KRAS* mutations are reportedly more rare in other populations from Asia (~5%) [25, 26] and populations of never smokers from Asia (~2%) [15, 18]. Our findings are consistent with a previous analysis of nonsmoking women in this region of the world,

which found that 22% of the lung tumors or sputum samples from Xuanwei harbored a *KRAS* mutation compared to 7% of samples from urban Beijing [27]. An additional study carried out in Xuanwei tumors found the frequency of *KRAS* mutations to be slightly higher (29%) [28]. Both of the previous studies [27, 28], as well as the current report, found a majority (>66%) of the *KRAS* mutations to be G to T.

Given that our population was from the a rural region of the Yunnan Province, whereas the populations used for previous characterizations of never smoking female lung tumors were selected from urban Shanghai and Beijing, our divergent findings for *KRAS* mutations and *EGFR* mutations on exons 18 and 21 may be due to the varying environmental exposures in urban versus rural China. The main difference in environmental exposures is likely indoor air pollution associated with in-home solid fuel use. The primary source of indoor air pollution in Xuanwei is smoke from domestic fuel combustion for heating and cooking, with most residents burning bituminous coal and some anthracite coal and wood. Xuanwei residents, and more specifically the women who primarily do all of the cooking, experience substantial exposures to indoor air pollution attributed to coal burning [29]. In Shanghai and Beijing, most residents typically use modern fuel sources, such as natural gas or electricity, for their heating and cooking needs.

Coal combustion for heating and cooking increases the levels in the home of known carcinogens, such as polycyclic aromatic hydrocarbons (PAHs) [30]. Although more research is needed to determine which coal constituent(s) is driving the risk of lung cancer associated with household coal use, it is conceivable that there may be mutation patterns in lung cancer tumors that will vary based on not only smoking status, but also these environmental exposures experienced by the patient. In support of our hypothesis, PAHs have been shown to increase intracellular calcium in human cell lines [31], which may lead to *EGFR*-dependant cell proliferation [32, 33]. PAH-DNA adducts have also been observed in bronchoalveolar lavage in Xuanwei residents burning coal [34], suggesting that the lung tumors in our never smoking tissues are being induced by coal combustion byproducts, such as PAHs, potentially leading to unique mutational patterns. Further, mutations in the p53 gene in tumor samples from nonsmoking women in Xuanwei were consistent with those of PAHs and different from those of lung cancer tumors from smokers [28]. This previous study in Xuanwei found that 76% of the mutations in *TP53* were G > T and that 33% of all the mutations clustered at a GC-rich region, which is a preferred binding site for PAHs. Additional evidence for the role of PAHs in the mutation spectrum was demonstrated by the fact that smoky coal condensate induced primarily G > T mutations at a frequency (78–86%) that was similar to that of B[a]P (77%) in *Salmonella* [35]. Since most of the mutations observed in our study were G to T transversions and some G to C transversions, which are rarely observed in other populations, our findings suggest that coal-derived carcinogens (i.e., PAHs) are the etiologic agent in this population.

In conclusion, the tissues from our never smoking female population harbored a strikingly divergent mutational pattern for *EGFR* and *KRAS*, specifically with respect to *EGFR* exon 18, *EGFR* exon 21, compared to other never smoking female populations in Asia. Our findings have helped evaluate the impact coal combustion byproducts have on the lung, and provide new insights into the pathogenesis of lung cancer among never smoking females exposed to indoor air pollution from coal. We found that mutations in *KRAS* and *EGFR* were mutually exclusive, potentially suggesting differing carcinogenic pathways; however, additional research is needed to determine if these mutations are indeed driver mutations or merely passenger mutations [36]. Due to our small sample size, caution should be used when drawing conclusions from our results, particularly from subset analyses, until these findings are replicated in a larger study. Our results can serve as a comparative model for the study of lung cancer tumors from never smoking females without this exposure, both in Asia

and elsewhere, and also highlight the potential importance of integrating environmental exposure histories into clinical and translational research. In this vein, however, our results may only be relevant to similar populations, with similar histologies and grades of lung cancer. Efforts should be made to evaluate the driver mutation spectra of subjects who use additional household fuel sources beyond only coal, which was the case for most of our subjects. Future research is needed to integrate additional exposure data exploring coal use dose-response analyses in terms of duration, intensity, and amount of coal use and exposure to environmental tobacco smoke.

Acknowledgments

Funding: The Intramural National Cancer Institute (N01-CO-12400) program funded the work. WP was also funded through R01-CA121210.


References

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin.* 2005; 55:74–108. [PubMed: 15761078]
2. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers--a different disease. *Nat Rev Cancer.* 2007; 7:778–790. [PubMed: 17882278]
3. Subramanian J, Govindan R. Lung cancer in never smokers: a review. *J Clin Oncol.* 2007; 25:561–570. [PubMed: 17290066]
4. Lee YJ, Kim JH, Kim SK, Ha SJ, Mok TS, et al. Lung cancer in never smokers: change of a mindset in the molecular era. *Lung Cancer.* 2011; 72:9–15. [PubMed: 21272954]
5. Lam WK. Lung cancer in Asian women-the environment and genes. *Respirology.* 2005; 10:408–417. [PubMed: 16135162]
6. Mumford JL, He XZ, Chapman RS, Cao SR, Harris DB, et al. Lung cancer and indoor air pollution in Xuan Wei, China. *Science.* 1987; 235:217–220. [PubMed: 3798109]
7. Hosgood HD, Boffetta P III, Greenland S, Lee Y-CA, McLaughlin J, et al. In-Home Coal and Wood Use and Lung Cancer Risk: A Pooled Analysis of the International Lung Cancer Consortium. *Environ Health Perspect.* 2010; 118:1743–1747. [PubMed: 20846923]
8. Lan Q, He XZ. Molecular epidemiological studies on the relationship between indoor coal burning and lung cancer in Xuan Wei, China. *Toxicology.* 2004; 198:301–305. [PubMed: 15138056]
9. Chapman RS, Mumford JL, Harris DB, He ZZ, Jiang WZ, et al. The epidemiology of lung cancer in Xuan Wei, China: current progress, issues, and research strategies. *Arch Environ Health.* 1988; 43:180–185. [PubMed: 3377554]
10. Lan Q, Chapman RS, Schreinemachers DM, Tian L, He X. Household stove improvement and risk of lung cancer in Xuanwei, China. *J Natl Cancer Inst.* 2002; 94:826–835. [PubMed: 12048270]
11. Hosgood HD, Chapman R, Shen M, Blair A, Chen E, et al. Portable stove use is associated with lower lung cancer mortality risk in lifetime smoky coal users. *British Journal of Cancer.* 2008; 99:1934–1939. [PubMed: 19034286]
12. Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F, et al. Carcinogenicity of household solid fuel combustion and of high-temperature frying. *Lancet Oncol.* 2006; 7:977–978. [PubMed: 17348122]
13. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. *The Lancet Oncology.* 2011; 12:175–180. [PubMed: 21277552]
14. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, et al. Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers. *Journal of the National Cancer Institute.* 2005; 97:339–346. [PubMed: 15741570]
15. Sun Y, Ren Y, Fang Z, Li C, Fang R, et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. *J Clin Oncol.* 2010; 28:4616–4620. [PubMed: 20855837]


16. Li C, Fang R, Sun Y, Han X, Li F, et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. *PLoS ONE*. 2011; 6:e28204. [PubMed: 22140546]
17. Lee YJ, Cho BC, Jee SH, Moon JW, Kim SK, et al. Impact of Environmental Tobacco Smoke on the Incidence of Mutations in Epidermal Growth Factor Receptor Gene in Never-Smoker Patients With Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology*. 2010; 28:487–492. [PubMed: 20008630]
18. Kawaguchi T, Ando M, Kubo A, Takada M, Atagi S, et al. Long Exposure of Environmental Tobacco Smoke Associated with Activating EGFR Mutations in Never-Smokers with Non-Small Cell Lung Cancer. *Clinical Cancer Research*. 2011; 17:39–45. [PubMed: 21059816]
19. Taga M, Mechanic LE, Hagiwara N, Vahakangas KH, Bennett WP, et al. EGFR somatic mutations in lung tumors: radon exposure and passive smoking in former- and never-smoking U.S. women. *Cancer Epidemiol Biomarkers Prev*. 2012; 21:988–992. [PubMed: 22523180]
20. Su Z, Dias-Santagata D, Duke M, Hutchinson K, Lin YL, et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. *J Mol Diagn*. 2011; 13:74–84. [PubMed: 21227397]
21. Zhang Y, Sun Y, Pan Y, Li C, Shen L, et al. Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis. *Clinical Cancer Research*. 2012; 18:1947–1953. [PubMed: 22317764]
22. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. *Int J Cancer*. 2006; 118:257–262. [PubMed: 16231326]
23. Bae NC, Chae MH, Lee MH, Kim KM, Lee EB, et al. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. *Cancer Genetics and Cytogenetics*. 2007; 173:107–113. [PubMed: 17321325]
24. Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. *Nature*. 2012; 489:519–525. [PubMed: 22960745]
25. Wu CC, Hsu HY, Liu HP, Chang JW, Chen YT, et al. Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications. *Cancer*. 2008; 113:3199–3208. [PubMed: 18932251]
26. Koivunen JP, Kim J, Lee J, Rogers AM, Park JO, et al. Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. *Br J Cancer*. 2008; 99:245–252. [PubMed: 18594528]
27. Keohavong P, Lan Q, Gao WM, DeMarini DM, Mass MJ, et al. K-ras mutations in lung carcinomas from nonsmoking women exposed to unvented coal smoke in China. *Lung Cancer*. 2003; 41:21–27. [PubMed: 12826308]
28. DeMarini DM, Landi S, Tian D, Hanley NM, Li X, et al. Lung tumor KRAS and TP53 mutations in nonsmokers reflect exposure to PAH-rich coal combustion emissions. *Cancer Res*. 2001; 61:6679–6681. [PubMed: 11559534]
29. Mumford JL, Li X, Hu F, Lu XB, Chuang JC. Human exposure and dosimetry of polycyclic aromatic hydrocarbons in urine from Xuan Wei, China with high lung cancer mortality associated with exposure to unvented coal smoke. *Carcinogenesis*. 1995; 16:3031–3036. [PubMed: 8603481]
30. IARC. Polynuclear aromatic compounds; Humans IMotEotCRt, editor. Lyon: International Agency for Research on Cancer Monographs on the Evaluation of the Carcinogenic Risks to Humans; 1983.
31. Tannheimer SL, Barton SL, Ethier SP, Burchiel SW. Carcinogenic polycyclic aromatic hydrocarbons increase intracellular Ca²⁺ and cell proliferation in primary human mammary epithelial cells. *Carcinogenesis*. 1997; 18:1177–1182. [PubMed: 9214600]
32. Ethier SP, Cundiff KC. Importance of Extended Growth Potential and Growth Factor Independence on in Vivo Neoplastic Potential of Primary Rat Mammary Carcinoma Cells. *Cancer Research*. 1987; 47:5316–5322. [PubMed: 3115564]
33. Ethier SP, Chiodino C, Jones RF. Role of Growth Factor Synthesis in the Acquisition of Insulin/Insulin-like Growth Factor I Independence in Rat Mammary Carcinoma Cells. *Cancer Research*. 1990; 50:5351–5357. [PubMed: 1696849]

34. Mumford JL, Lee XM, Lewtas J, Young TL, Santella RM. DNA Adducts as Biomarkers for Assessing Exposure to Polycyclic Aromatic-Hydrocarbons in Tissues from Xuan-Wei Women with High Exposure to Coal Combustion Emissions and High Lung-Cancer Mortality. *Environmental Health Perspectives*. 1993; 99:83–87. [PubMed: 8319664]
35. Granville CA, Hanley NM, Mumford JL, DeMarini DM. Mutation spectra of smoky coal combustion emissions in *Salmonella* reflect the TP53 and KRAS mutations in lung tumors from smoky coal-exposed individuals. *Mutat Res*. 2003; 525:77–83. [PubMed: 12650907]
36. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, et al. Cancer genome landscapes. *Science*. 2013; 339:1546–1558. [PubMed: 23539594]


(a) Adenocarcinomas



(b) Squamous Cell Carcinomas



(c) All Lung Cancers



	<i>EGFR</i> Point Mutation	<i>EGFR</i> Deletion	<i>EGFR</i> Insertion	<i>KRAS</i> Point Mutation	Wildtype	Total
Adenocarcinomas	8	3	1	5	15	32
Squamous cell carcinomas	1	1	0	1	4	7
All lung cancers	9	4	1	6	20	40

Figure 1. *EGFR* point mutations, insertions, and deletions, and *KRAS* point mutations detected in never smoking female (a) adenocarcinomas, (b) squamous cell carcinomas, and (c) all lung cancers†
 † *EGFR* and *KRAS* point mutations, insertions, and deletions were mutually exclusive; One tissue had two unique *EGFR* point mutations; All lung cancers includes the adenosquamous cell carcinoma case in addition to the adenocarcinomas and squamous cell carcinomas




Figure 2.

Distribution of *EGFR* exon 18 point mutations, exon 19 deletions, exon 20 insertions, and exon 21 point mutations in never smoking female adenocarcinomas (n = 32), squamous cell carcinomas (n = 7), and all lung cancers (n = 40) from Xuanwei, China†.

† One tissue had two unique *EGFR* point mutations; Total number of *EGFR* point mutations, deletions, and insertions present in the Xuanwei samples is 12 among adenocarcinomas, 2 among squamous cell carcinomas, and 14 among all lung cancers; * Mutation rates among never smoking females in Asia reported by (Zhang et al 2012); ** Mutation rates typically found when summarizing all lung cancer histologies, across multiple ethnicities including both those that do and do not smoke tobacco, reported by (Shigematsu and Gazdar 2006).

Table 1

Tumor and patient characteristics of never smoking female lung cancers from Xuanwei, China

	Adenocarcinoma n = 32		Squamous Cell Carcinoma n = 7		Adenosquamous n = 1		All Lung Cancer Cases n = 40	
	n	%	n	%	n	%	n	%
Age (mean ± std)	46.6 ± 10.1		45.7 ± 10.6		48.0 ± not applicable		46.5 ± 10.0	
Differentiation								
Well differentiated	6	18.8	1	14.3	0	0.0	7	17.5
Moderately differentiated	21	65.6	4	57.1	0	0.0	25	62.5
Poorly differentiated	4	12.5	2	28.6	1	100.0	7	17.5
Missing	1	3.1	0	0.0	0	0.0	1	2.5
Fuel used for heating and cooking								
Coal only	29	90.6	4	57.1	0	0.0	33	82.5
Coal and wood	1	3.1	0	0.0	0	0.0	1	2.5
Electricity	0	0.0	2	28.6	0	0.0	2	5.0
Missing	2	6.3	1	14.3	1	100.0	4	10.0

Associations between clinicopathologic characteristics and *EGFR* and *KRAS* events among never smoking female lung cancer patients[†]

Table 2

	Wildtype			<u>EGFR point mutations, deletions, and insertions</u>			<u>KRAS point mutations</u>			
	n	%	P-value ^{††}	absent	present	P-value ^{†††}	absent	present	P-value ^{†††}	
Age										
<50 years old	11	57.9	14	56.0	5	35.7	16	48.5	3	50.0
50 years old	8	42.1	11	44.0	9	64.3	17	51.5	3	50.0
Histology										
Adenocarcinoma	15	78.9	20	80.0	12	85.7	27	81.8	5	83.3
Squamous Cell Carcinoma	4	21.1	5	20.0	2	14.3	6	18.2	1	16.7
Differentiation										
Well differentiated	4	21.1	4	16.0	3	21.4	7	21.2	0	0.0
Moderately differentiated	11	57.9	16	64.0	9	64.3	20	60.6	5	83.3
Poorly differentiated	3	15.8	4	16.0	2	14.3	5	15.2	1	16.7

[†] Restricted to adenocarcinomas and squamous cell carcinomas; Wildtype subjects are defined as having no *EGFR* point mutations, deletions, or insertions, and no *KRAS* point mutations; P-values determined by Chi-squared and Fischer's exact tests

^{††} P-value for *EGFR* point mutations, deletions, and insertions being present versus absent, or *KRAS* point mutations being present versus absent, respectively

^{†††} P-value for *EGFR* point mutations, deletions, and insertions being present versus wildtype, or *KRAS* point mutations being present versus wildtype, respectively

Table 3
EGFR and *KRAS* point mutations, deletions, and insertions in never smoking lung cancer tumors

Gene	Event	Description	Histology	Differentiation	Age	Fuel Used for Heating and Cooking**	
<i>EGFR</i>	Point Mutation						
		EGFR_G719A_2156G>C*	Adenocarcinoma	Well	40	Only Coal	
		EGFR_L858R_2573T>G	Adenocarcinoma	Well	40	Only Coal	
		EGFR_G719C_2155G>T	Adenocarcinoma	Well	56	Only Coal	
		EGFR_G719A_2156G>C	Adenocarcinoma	Moderately	52	Only Coal	
		EGFR_G719C_2155G>T	Adenocarcinoma	Moderately	52	Only Coal	
		EGFR_L858R_2573T>G	Adenocarcinoma	Moderately	58	Only Coal	
		EGFR_G719S_2155G>T	Adenocarcinoma	Poorly	30	Only Coal	
		EGFR_G719S_2155G>A	Adenocarcinoma	Poorly	40	Only Coal	
		EGFR_G719C_2155G>T	Squamous Cell Carcinoma	Moderately	58	Only Coal	
	Deletion						
		EGFR_19-15bpDel	Adenocarcinoma	Moderately	43	Only Coal	
		EGFR_19-15bpDel	Adenocarcinoma	Moderately	52	Unknown	
	EGFR_19-15bpDel	Adenocarcinoma	Moderately	58	Coal and Wood		
	EGFR_19-15bpDel	Squamous Cell Carcinoma	Moderately	50	Electric		
Insertion							
	E20-6bp-ins.	Adenocarcinoma	Moderately	50	Only Coal		
<i>KRAS</i>	Point Mutation						
		KRAS(R)G12C_34G>T	Adenocarcinoma	Moderately	30	Only Coal	
		KRAS(R)G12C_34G>T	Adenocarcinoma	Moderately	40	Only Coal	
		KRAS(R)G12C_34G>T	Adenocarcinoma	Moderately	50	Only Coal	
		KRAS(R)G12C_34G>T	Adenocarcinoma	Moderately	52	Only Coal	
		KRAS(R)G12C_34G>T	Adenocarcinoma	Moderately	52	Only Coal	
		KRAS(R)G12C_34G>T	Squamous Cell Carcinoma	Poorly	24	Only Coal	

* This tumor also had a second *EGFR* point mutation [EGFR(R)L861Q_2582T>A]

** Type of fuel currently used at the time of surgery